Metformin: A novel biological modifier of tumor response to radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 2, 2015, Pages 454-464

  Koritzinsky, Marianne ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; DISEASES; PATIENT MONITORING; RADIATION; STEM CELLS; TUMORS;

ANTI-DIABETIC DRUGS; BIOLOGICAL MODIFIERS; EXPERIMENTAL MODELS; GENETIC BACKGROUNDS; RADIATION RESPONSE; RADIO-SENSITIZATION; RETROSPECTIVE ANALYSIS; THERAPEUTIC RATIOS;

RADIOTHERAPY;

METFORMIN; PROTEIN KINASE LKB1; PROTEIN P53; ANTIDIABETIC AGENT; RADIOSENSITIZING AGENT;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL FRACTIONATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG MECHANISM; DRUG UPTAKE; HUMAN; HYPOXIA; IMAGE GUIDED RADIOTHERAPY; IONIZING RADIATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; ANIMAL; CELL HYPOXIA; DIABETES MELLITUS; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY; RADIATION DOSE;

ANIMALS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84941284287     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.06.003     Document Type: Review

References (109)

1. M.N. Pollak Investigating metformin for cancer prevention and treatment: The end of the beginning Cancer Discov 2 2012 778 790
2. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, and et al. Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
3. M. Franciosi, G. Lucisano, E. Lapice, and et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review PLoS One 8 2013 e71583
4. S. Jiralerspong, S.L. Palla, S.H. Giordano, and et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer J Clin Oncol 27 2009 3297 3302
5. D. Margel, D.R. Urbach, L.L. Lipscombe, and et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
6. W. Wu, K. Merriman, A. Nabaah, and et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma Br J Cancer 111 2014 628 636
7. E.M. Ko, P. Walter, A. Jackson, and et al. Metformin is associated with improved survival in endometrial cancer Gynecol Oncol 132 2014 438 442
8. M. Rieken, E. Xylinas, L. Kluth, and et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer BJU Int 112 2013 1105 1112
9. D.E. Spratt, C. Zhang, Z.S. Zumsteg, and et al. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality Eur Urol 63 2013 709 716
10. N. Sadeghi, J.L. Abbruzzese, S.C. Yeung, and et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer Clin Cancer Res 18 2012 2905 2912
11. I. Laskov, L. Drudi, M.C. Beauchamp, and et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer Gynecol Oncol 134 2014 607 614
12. A. Mitsuhashi, T. Kiyokawa, Y. Sato, and et al. Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial Cancer 120 2014 2986 2995
13. A.M. Joshua, V.E. Zannella, M.R. Downes, and et al. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer Prostate Cancer Prostatic Dis 17 2014 252 258
14. S. Niraula, R.J. Dowling, M. Ennis, and et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study Breast Cancer Res Treat 135 2012 821 830
15. K. Hosono, H. Endo, H. Takahashi, and et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev Res (Phila) 3 2010 1077 1083
16. S. Hadad, T. Iwamoto, L. Jordan, and et al. Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial Breast Cancer Res Treat 128 2011 783 794
17. X. Huang, S. Wullschleger, N. Shpiro, and et al. Important role of the lkb1-ampk pathway in suppressing tumorigenesis in pten-deficient mice Biochem J 412 2008 211 221
18. A. Tomimoto, H. Endo, M. Sugiyama, and et al. Metformin suppresses intestinal polyp growth in apcmin/+ mice Cancer Sci 99 2008 2136 2141
19. M. Zakikhani, R. Dowling, I.G. Fantus, and et al. Metformin is an amp kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 2006 10269 10273
20. R.M. Memmott, J.R. Mercado, C.R. Maier, and et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis Cancer Prev Res (Phila) 3 2010 1066 1076
21. V.N. Anisimov, L.M. Berstein, P.A. Egormin, and et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in her-2/neu transgenic mice Exp Gerontol 40 2005 685 693
22. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res 69 2009 7507 7511
23. M.B. Schneider, H. Matsuzaki, J. Haorah, and et al. Prevention of pancreatic cancer induction in hamsters by metformin Gastroenterology 120 2001 1263 1270
24. M. Buzzai, R.G. Jones, R.K. Amaravadi, and et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res 67 2007 6745 6752
25. I. Ben Sahra, K. Laurent, A. Loubat, and et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin d1 level Oncogene 27 2008 3576 3586
26. A. Vazquez-Martin, C. Oliveras-Ferraros, and J.A. Menendez The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells Cell Cycle 8 2009 88 96
27. K. Kisfalvi, G. Eibl, J. Sinnett-Smith, and et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth Cancer Res 69 2009 6539 6545
28. L.A. Cantrell, C. Zhou, A. Mendivil, and et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy Gynecol Oncol 116 2010 92 98
29. R. Rattan, R.P. Graham, J.L. Maguire, and et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo Neoplasia 13 2011 483 491
30. G.Z. Rocha, M.M. Dias, E.R. Ropelle, and et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth Clin Cancer Res 17 2011 3993 4005
31. V.E. Zannella, A.D. Pra, H. Muaddi, and et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response Clin Cancer Res 19 2013 6741 6750
32. H.D. Skinner, M.R. McCurdy, A.E. Echeverria, and et al. Metformin use and improved response to therapy in esophageal adenocarcinoma Acta Oncol 52 2013 1002 1009
33. H.D. Skinner, C.H. Crane, C.R. Garrett, and et al. Metformin use and improved response to therapy in rectal cancer Cancer Med 2 2013 99 107
34. H.D. Skinner, V.C. Sandulache, T.J. Ow, and et al. Tp53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence Clin Cancer Res 18 2012 290 300
35. A. Ferro, S. Goyal, S. Kim, and et al. Evaluation of diabetic patients with breast cancer treated with metformin during adjuvant radiotherapy Int J Breast Cancer 2013 2013 659723
36. Y. Storozhuk, S.N. Hopmans, T. Sanli, and et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK Br J Cancer 108 2013 2021 2032
37. T. Zhang, L. Zhang, T. Zhang, and et al. Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo Radiat Res 181 2014 641 649
38. C.W. Song, H. Lee, R.P. Dings, and et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells Sci Rep 2 2012 362
39. M.R. Owen, E. Doran, and A.P. Halestrap Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem J 348 Pt 3 2000 607 614
40. W.W. Wheaton, S.E. Weinberg, R.B. Hamanaka, and et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis Elife 3 2014 e02242
41. A.K. Madiraju, D.M. Erion, Y. Rahimi, and et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase Nature 510 2014 542 546
42. G. Zhou, R. Myers, Y. Li, and et al. Role of amp-activated protein kinase in mechanism of metformin action J Clin Invest 108 2001 1167 1174
43. S.A. Hawley, F.A. Ross, C. Chevtzoff, and et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of ampk activation Cell Metab 11 2010 554 565
44. G.R. Steinberg, and B.E. Kemp AMPK in health and disease Physiol Rev 89 2009 1025 1078
45. I. Pernicova, and M. Korbonits Metformin-mode of action and clinical implications for diabetes and cancer Nat Rev Endocrinol 10 2014 143 156
46. R.A. Miller, Q. Chu, J. Xie, and et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic amp Nature 494 2013 256 260
47. J.A. Baur, and M.J. Birnbaum Control of gluconeogenesis by metformin: Does redox trump energy charge? Cell Metab 20 2014 197 199
48. V. Sharma, and J.H. McNeill To scale or not to scale: The principles of dose extrapolation Br J Pharmacol 157 2009 907 921
49. T. Sanli, A. Rashid, C. Liu, and et al. Ionizing radiation activates amp-activated kinase (ampk): A target for radiosensitization of human cancer cells Int J Radiat Oncol Biol Phys 78 2010 221 229
50. Y. Zhang, S.J. Storr, K. Johnson, and et al. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy Oncotarget 5 2014 12936 12949
51. E.H. Kim, M.S. Kim, C.K. Cho, and et al. Low and high linear energy transfer radiation sensitization of HCC cells by metformin J Radiat Res 55 2014 432 442
52. A. Fasih, H.A. Elbaz, M. Huttemann, and et al. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway Radiat Res 182 2014 50 59
53. H. Muaddi, S. Chowdhury, R. Vellanki, and et al. Contributions of ampk and p53 dependent signaling to radiation response in the presence of metformin Radiother Oncol 108 2013 446 450
54. R.C. Miller, J.S. Murley, and D.J. Grdina Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs Radiat Res 181 2014 464 470
55. J. Liu, M. Hou, T. Yuan, and et al. Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair Oncol Rep 28 2012 1406 1412
56. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ros-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8 2009 579 591
57. M.D. Brand The sites and topology of mitochondrial superoxide production Exp Gerontol 45 2010 466 472
58. M.D. Aldea, B. Petrushev, O. Soritau, and et al. Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells J BUON 19 2014 502 511
59. A.B. Haugrud, Y. Zhuang, J.D. Coppock, and et al. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells Breast Cancer Res Treat 147 2014 539 550
60. C. Gorrini, I.S. Harris, and T.W. Mak Modulation of oxidative stress as an anticancer strategy Nat Rev Drug Discov 12 2013 931 947
61. L.B. Sullivan, and N.S. Chandel Mitochondrial reactive oxygen species and cancer Cancer Metab 2 2014 17
62. N. Ouslimani, J. Peynet, D. Bonnefont-Rousselot, and et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells Metabolism 54 2005 829 834
63. X. Hou, J. Song, X.N. Li, and et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the ampk-foxo3 pathway Biochem Biophys Res Commun 396 2010 199 205
64. M. Mahrouf, N. Ouslimani, J. Peynet, and et al. Metformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase C Biochem Pharmacol 72 2006 176 183
65. C. Bellin, D.H. de Wiza, N.F. Wiernsperger, and et al. Generation of reactive oxygen species by endothelial and smooth muscle cells: Influence of hyperglycemia and metformin Horm Metab Res 38 2006 732 739
66. K.H. Vousden, and D.P. Lane P53 in health and disease Nat Rev Mol Cell Biol 8 2007 275 283
67. Y. Shiloh, and Y. Ziv The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more Nat Rev Mol Cell Biol 14 2013 197 210
68. R.G. Jones, D.R. Plas, S. Kubek, and et al. Amp-activated protein kinase induces a p53-dependent metabolic checkpoint Mol Cell 18 2005 283 293
69. J.M. Brown, and B.G. Wouters Apoptosis, p53, and tumor cell sensitivity to anticancer agents Cancer Res 59 1999 1391 1399
70. P.A. Muller, and K.H. Vousden P53 mutations in cancer Nat Cell Biol 15 2013 2 8
71. V.E. Zannella, D. Cojocari, S. Hilgendorf, and et al. Ampk regulates metabolism and survival in response to ionizing radiation Radiother Oncol 99 2011 293 299
72. J.J. Shank, K. Yang, J. Ghannam, and et al. Metformin targets ovarian cancer stem cells in vitro and in vivo Gynecol Oncol 127 2012 390 397
73. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Del Barco, and et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Breast Cancer Res Treat 126 2011 355 364
74. B. Bao, Z. Wang, S. Ali, and et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating mirnas in pancreatic cancer cells Cancer Prev Res (Phila) 5 2012 355 364
75. J.W. Jung, S.B. Park, S.J. Lee, and et al. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated oct4 expression PLoS One 6 2011 e28068
76. A. Sato, J. Sunayama, M. Okada, and et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK Stem Cells Transl Med 1 2012 811 824
77. A. Vazquez-Martin, S. Cufi, E. Lopez-Bonet, and et al. Metformin limits the tumourigenicity of ips cells without affecting their pluripotency Sci Rep 2 2012 964
78. P. Zhu, M. Davis, A.J. Blackwelder, and et al. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models Cancer Prev Res (Phila) 7 2014 199 210
79. Y. Zhang, M. Guan, Z. Zheng, and et al. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients PLoS One 8 2013 e81264
80. K. Kalinsky, K.D. Crew, S. Refice, and et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer Cancer Invest 32 2014 150 157
81. R.J. Dowling, M. Zakikhani, I.G. Fantus, and et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
82. I. Ben Sahra, C. Regazzetti, G. Robert, and et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1 Cancer Res 71 2011 4366 4372
83. A. Kalender, A. Selvaraj, S.Y. Kim, and et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner Cell Metab 11 2010 390 401
84. D.B. Shackelford, E. Abt, L. Gerken, and et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin Cancer Cell 23 2013 143 158
85. R. Sarfstein, Y. Friedman, Z. Attias-Geva, and et al. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners PLoS One 8 2013 e61537
86. G. Yi, Z. He, X. Zhou, and et al. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway Int J Oncol 43 2013 1503 1510
87. V.C. Sandulache, H.D. Skinner, T.J. Ow, and et al. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status Cancer 118 2012 711 721
88. I. Ben Sahra, K. Laurent, S. Giuliano, and et al. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells Cancer Res 70 2010 2465 2475
89. I. Ben Sahra, J.F. Tanti, and F. Bost The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells Autophagy 6 2010 670 671
90. K. Birsoy, R. Possemato, F.K. Lorbeer, and et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides Nature 508 2014 108 112
91. B.G. Wouters, S.A. Weppler, M. Koritzinsky, and et al. Hypoxia as a target for combined modality treatments Eur J Cancer 38 2002 240 257
92. J. Overgaard Hypoxic radiosensitization: Adored and ignored J Clin Oncol 25 2007 4066 4074
93. J. Overgaard Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis Radiother Oncol 100 2011 22 32
94. T.W. Secomb, R. Hsu, E.T. Ong, and et al. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors Acta Oncol 34 1995 313 316
95. J.E. Biaglow, and R.E. Durand The effects of nitrobenzene derivatives on oxygen utilization and radiation response of an in vitro tumor model Radiat Res 65 1976 529 539
96. R.E. Durand, and J.E. Biaglow Radiosensitization of hypoxic cells of an in vitro tumor model by respiratory inhibitors Radiat Res 69 1977 359 366
97. J.E. Biaglow, C.L. Greenstock, and R.E. Durand Effects of sensitizers on cell respiration: 1. Factors influencing the effects of hypoxic cell radiosensitizers on oxygen utilization of tumour and cultured mammalian cells Br J Cancer Suppl 3 1978 145 149
98. J.E. Biaglow, and R.E. Durand The enhanced radiation response of an in vitro tumour model by cyanide released from hydrolysed amygdalin Int J Radiat Biol Relat Stud Phys Chem Med 33 1978 397 401
99. C. Diepart, O. Karroum, J. Magat, and et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors Cancer Res 72 2012 482 490
100. P.J. Goodwin, W.R. Parulekar, K.A. Gelmon, and et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32 J Natl Cancer Inst 107 2015
101. A. DeCensi, M. Puntoni, S. Gandini, and et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial Breast Cancer Res Treat 148 2014 81 90
102. M.M. Christensen, C. Brasch-Andersen, H. Green, and et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c Pharmacogenet Genomics 21 2011 837 850
103. M.L. Becker, L.E. Visser, R.H. van Schaik, and et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus Pharmacogenomics J 9 2009 242 247
104. I. Tkac, L. Klimcakova, M. Javorsky, and et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes Diabetes Obes Metab 15 2013 189 191
105. S.L. Stocker, K.M. Morrissey, S.W. Yee, and et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin Clin Pharmacol Ther 93 2013 186 194
106. J.H. Choi, S.W. Yee, A.H. Ramirez, and et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin Clin Pharmacol Ther 90 2011 674 684
107. R.J. Dowling, S. Niraula, M.C. Chang, and et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: A prospective window of opportunity neoadjuvant study Breast Cancer Res 17 2015 540
108. K. Toustrup, B.S. Sorensen, P. Lassen, and et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck Radiother Oncol 102 2012 122 129
109. E. Lalonde, A.S. Ishkanian, J. Sykes, and et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study Lancet Oncol 15 2014 1521 1532